Starting from December 31, 2023, Hualing Pharmaceuticals will change the method of communication according to the new listing rules of the Hong Kong Stock Exchange and the company's articles of association. In the future, the company will mainly send communications to shareholders via email and only provide print formats when requested by shareholders. This arrangement requires shareholders to provide valid email addresses. If shareholders fail to provide or if the addresses are invalid, the company will send print copies according to established procedures. The company's communications will also be published on the company and the HKEX websites and will be notified to shareholders via email or post. Shareholders can also scan QR codes or contact the Hong Kong Stock Transfer Registration Office to provide email addresses or request printed copies of the company's communications.

Starting from December 31, 2023, Hualing Pharmaceuticals will change the method of communication according to the new listing rules of the Hong Kong Stock Exchange and the company's articles of association. In the future, the company will mainly send communications to shareholders via email and only provide print formats when requested by shareholders. This arrangement requires shareholders to provide valid email addresses. If shareholders fail to provide or if the addresses are invalid, the company will send print copies according to established procedures. The company's communications will also be published on the company and the HKEX websites and will be notified to shareholders via email or post. Shareholders can also scan QR codes or contact the Hong Kong Stock Transfer Registration Office to provide email addresses or request printed copies of the company's communications.